Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71250 ↗At a glance
Journal article in Diabetes, Obesity and Metabolism, 2026. Written by Navneet Upadhyay and 5 co-authors. Institution: Eli Lilly and Company, Indianapolis, Indiana, USA. Major MEDLINE topics: Tirzepatide, Health Care Costs, Obesity, Overweight. 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Eli Lilly and Company.
Topics: Diabetes mellitus
Abstract (original language)
Aims
Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025. Adults > 55 years with obesity, or overweight with ≥ 1 weight‐related comorbidity, without T2 diabetes who initiated tirzepatide for weight management were compared with propensity score‐matched individuals who did not receive any incretin‐based therapies. Changes in all‐cause healthcare costs (excluding tirzepatide; per‐person‐per‐month) between cohorts were assessed at 3–6, 6–12 and 12–18 months using a difference in differences (DiD) framework. Informative censoring and differential follow‐up were addressed with inverse‐probability‐of‐censoring‐weights and pairwise censoring.
Results
Each cohort comprised 15843 individuals. Healthcare cost DiD estimates (95% CI) for the tirzepatide versus control cohorts were −$145 (−266, −25; 12.3% reduction; p = 0.022) during 6–12 months and −$319 (−544, −94; 25.4% reduction; p = 0.015) during 12–18 months; using pairwise censoring, estimates were −$181 (−319, −43; p = 0.021) and −$607 (−1007, −207; p = 0.023), respectively. Cost offsets with tirzepatide were driven by higher medical costs in controls during 12–18 months (−$211 [−$407, −$15]; p = 0.065) and fewer inpatient/emergency department visits with tirzepatide versus controls; incidence rate ratio (95% CI) 0.69 (0.50, 0.94; p = 0.021) during 12–18 months.
Conclusions
Monthly cost offsets for persistent tirzepatide users versus untreated individuals grew over time, offsetting $319 (ranging from $94 to $544) tirzepatide costs by 12–18 months. These results have implications for the $195 monthly net Medicare cost for the Bridge programme, suggesting tirzepatide may generate near‐term cost savings in an older population that stays on treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Cencora, Conshohocken, Pennsylvania, USA.
- Aixial Group, Boulogne-Billancourt, France.
ORCID profiles: Navneet Upadhyay, Emily R Hankosky
Funding
- Eli Lilly and Company
Cite
APA
Upadhyay, N., Bonakdar, A., Subedi, K., Banerjee, S., Behrend, B., & Hankosky, E. R. (2026). Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71250
Vancouver
Upadhyay N, Bonakdar A, Subedi K, Banerjee S, Behrend B, Hankosky ER. Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71250
BibTeX
@article{Upadhyay2026,
author = {Upadhyay, Navneet and Bonakdar, Ali and Subedi, Keshab and Banerjee, Soutrik and Behrend, Benjamin and Hankosky, Emily R},
title = {Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71250}
}
EUVIMED